⌘K
t
Shield Therapeutics plc announced the voting results for its 2025 Annual General Meeting held on 22 May 2025. All 12 resolutions presented were passed, with resolutions 1 to 10 passed as ordinary resolutions and resolutions 11 to 12 as special resolutions. Voting percentages for all resolutions ranged from 99.60% to 99.98% in favour, out of 1,041,690,484 shares in issue.
| Date | 22 May 2025 |
| Time | 17:06:33 |
| Category | AGMs and other meetings |
| ID | 8612J |
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Results of 2025 Annual General Meeting
London, UK, 22 May, 2025: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anemia ("ID/IDA"), announces the voting results for each resolution set out in the Notice of Annual General Meeting 2025. The Board reports that all resolutions were passed: 1 to 10 passed as ordinary resolutions and 11 to 12 passed as special resolutions.
The following table shows the votes cast on each resolution:
|
|
VOTES |
% |
VOTES AGAINST |
% |
WITHHELD VOTES |
|
Resolution 1 |
668,835,432 |
99.98% |
133,164 |
0.02% |
357,039 |
|
Resolution 2 |
668,122,080 |
99.89% |
757,837 |
0.11% |
445,718 |
|
Resolution 3 |
668,296,332 |
99.91% |
583,585 |
0.09% |
445,718 |
|
Resolution 4 |
668,137,993 |
99.89% |
741,976 |
0.11% |
445,666 |
|
Resolution 5 |
668,388,581 |
99.93% |
491,388 |
0.07% |
445,666 |
|
Resolution 6 |
668,133,181 |
99.89% |
741,976 |
0.11% |
450,478 |
|
Resolution 7 |
667,890,103 |
99.85% |
1,027,158 |
0.15% |
408,374 |
|
Resolution 8 |
668,672,292 |
99.96% |
291,492 |
0.04% |
361,851 |
|
Resolution 9 |
666,908,073 |
99.69% |
2,080,523 |
0.31% |
337,039 |
|
Resolution 10 |
666,442,645 |
99.60% |
2,643,451 |
0.40% |
239,539 |
|
Resolution 11 |
666,424,128 |
99.88% |
808,577 |
0.12% |
2,092,930 |
|
Resolution 12 |
666,417,127 |
99.88% |
793,851 |
0.12% |
2,114,657 |
Notes:
1. Number of shares in issue 1,041,690,484.
2. Details of the votes received on the resolutions are available on the Company's website:
https://www.shieldtherapeutics.com/corporate-documents/.
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.
For further information please contact:
|
Shield Therapeutics plc |
|
|
Anders Lundstrom, CEO
|
+44 (0) 191 511 8500 |
|
Santosh Shanbhag, CFO Stephanie Hicks, Investor Relations |
Investorrelations@shieldtx.com |
|
|
|
|
Nominated Adviser and Joint Broker |
|
|
Peel Hunt LLP |
|
|
James Steel |
+44 (0)20 7418 8900 |
|
|
|
|
Joint Broker |
+44 (0)20 7220 0500 |
|
Cavendish Ltd |
|
|
Geoff Nash / Rory Sale / Nigel Birks / Harriet Ward |
|
|
|
|
About Iron Deficiency and ACCRUFeR®/FeRACCRU®
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients.
ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has commercially launched its lead product ACCRUFeR® in the U.S. through an exclusive, multi-year collaboration with a commercial partner. Internationally, it has secured licensing agreements with four specialty pharmaceutical companies, enabling commercialisation across key markets. The product is currently marketed in the UK, European Union, Australia, and New Zealand as FeRACCRU®, with additional exclusive partnerships in place for China and surrounding regions, South Korea, and as ACCRUFeR® in Canada.
ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.
ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.